GET DAILY SIGNALSStarling Oncology (STLN) Shares Decline -45% Following Earnings Miss
Key Takeaways
- STLN shares fell roughly 45% over the past 30 days, from about $6.51 to near $3.58, with most of the decline occurring in a single trading session.
- The selloff followed a third-quarter 2026 earnings miss, as the company posted a wider-than-expected loss of $0.13 per share versus a consensus estimate near $0.05.
- Management narrowed its full-year 2026 revenue guidance to $650 million to $660 million, down from a prior range of $650 million to $670 million.
- Despite the miss, revenue rose 24% year over year to $169.8 million, and adjusted EBITDA turned positive for a second consecutive quarter at $3.4 million.
- Investor concerns centered on margin sustainability after the capitated segment's medical loss ratio climbed to 81.0% from 67.8% a year earlier.
- The reaction was delayed: the stock held steady on the report's release and plunged roughly 46% the following session on about seven times average volume.
- For deeper context on valuation and expectations, explore the company's Price Targets, Earnings, and Forecast pages.
- Discover automated trading ideas across the market by exploring Trending AI Robots.
Company Background and Market Position
Starling Oncology, Inc. (STLN), formerly The Oncology Institute, Inc., is a community-based oncology care provider headquartered in Cerritos, California. The company delivers outpatient cancer care through a network of clinics, a growing specialty pharmacy business, and value-based, capitated care arrangements with health plans. With approximately 641 employees, the company has been expanding its specialty pharmacy platform while transitioning toward alternative payment models designed to align incentives around patient outcomes.
Investors follow the stock for its exposure to structural trends in oncology care, including rising cancer volumes, a shift toward outpatient and community-based treatment, and the growth of specialty pharmaceuticals. The company went public in November 2021, and its recent reporting has emphasized a path toward sustained positive adjusted EBITDA, making profitability milestones and margin trends key watchpoints for the market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, STLN shares declined approximately 45%, falling from a closing price near $6.51 in mid-October to roughly $3.58. The move was not a gradual erosion; the overwhelming majority of the drop occurred on a single day in early November, when the stock fell roughly 46% from $6.70 to $3.62 on exceptionally heavy volume.
The quarterly picture is similar. About three months ago the stock traded near $6.45, meaning the quarter's decline is also approximately 45%. The shares had reached a 52-week high of $7.13 in mid-September after a multi-month rally, only to surrender nearly all of that advance following the latest earnings report. The one-session collapse erased the bulk of the prior quarter's gains and pushed the stock well below its longer-term moving averages.
What Drove the Recent Price Action
The principal catalyst was the company's third-quarter 2026 earnings report. Starling Oncology posted revenue of $169.8 million, up 24% year over year and modestly above analyst expectations, but the bottom line disappointed: a net loss of $15.7 million, or $0.13 per share, compared with a consensus loss estimate near $0.05 per share. Management also narrowed its full-year revenue guidance, trimming the top end to $660 million.
Investors focused on two profitability signals. First, the company's capitated, or value-based, business grew revenue 40% to $28.7 million, but its medical loss ratio deteriorated sharply to 81.0% from 67.8% a year earlier, suggesting the rapid expansion carried meaningful margin compression. Second, while specialty pharmacy revenue jumped 44% to $109.3 million with segment gross margins of 24.2%, the overall earnings shortfall raised questions about the sustainability of the growth model. I reviewed comparable signals with Tickeron’s AI Trend Prediction Engine for additional perspective.
The price reaction was unusually delayed. The results were released after the market close on November 5, and the stock initially traded relatively flat. The following session, the market repriced the shares sharply lower, with volume roughly seven times the 20-day average, as investors digested the profitability gap and the reduced guidance.
Performance Trends Over the Past Quarter
The broader quarterly trend reflects a reversal of investor optimism that had built through much of 2026. The stock climbed from around $5 in early August to its 52-week high of $7.13 in mid-September, supported by strong top-line growth, progress toward positive adjusted EBITDA, and enthusiasm around the specialty pharmacy expansion. An earlier quarterly report contributed to a notable single-day jump in early August, reinforcing a bullish tone.
That momentum stalled as the company approached its most recent earnings. The third-quarter shortfall on earnings per share, the deterioration in capitated medical loss ratios, and the modest guidance trim undermined the growth narrative that had driven the rally. In effect, the quarter's entire move was compressed into one sharp repricing event that reset expectations for the stock, leaving it trading near levels last seen before the summer advance.
Factors Investors Should Monitor Next
Investors should monitor several factors in the coming quarters. The company's ability to deliver on its reaffirmed commitment to full-year adjusted EBITDA positivity will be tested when fourth-quarter results arrive. The trajectory of the capitated segment's medical loss ratio is a central question, as further deterioration would pressure the value-based care thesis, while stabilization would support the growth narrative. Specialty pharmacy margin trends and revenue growth will also be closely watched.
Analyst revisions represent another signal: with consensus price targets averaging near $9 before the selloff, subsequent estimate adjustments could establish a new baseline for the stock. Broader reimbursement dynamics in oncology, competitive pressures in specialty pharmacy distribution, and the pace of the company's transition to value-based contracts remain key industry-level factors. Investors should weigh these drivers alongside the company's own guidance updates before forming conclusions. From what I see, these elements will shape the next phase for the shares.
Leveraging AI Trading Bots for Additional Context
In my own process, I often review Tickeron’s AI Trading Bots to explore a range of automated strategies that monitor market activity. These tools provide performance data across different approaches and timeframes, which I find useful as a supplement when evaluating how broader sentiment might influence individual names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Momentum Indicator for STLN turns negative, indicating new downward trend
STLN saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned negative. In 68 of the 74 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for STLN turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 35 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
STLN moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STLN crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for STLN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +19.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where STLN advanced for three days, in 258 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
STLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-14.808) is normal, around the industry mean (204.532). P/E Ratio (-12.483) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (1.124) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. STLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement